跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 156 条关于
“ARID1A”
全部
156
临床试验
93
药物
15
机构
12
资讯
36
2年前
NXP800 Receives FDA Orphan Drug Designation for ARID1a-Deficient Ovarian Cancers
去年
Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial
去年
Nuvectis Pharma Reports Financial Results and Highlights Clinical Progress of NXP800 and NXP900
2年前
IL-21 Enhanced NK Cells Show Promise in Glioblastoma; Pembrolizumab Trials Halted
2个月前
Personalized Vaccines Plus Checkpoint Inhibitors Proposed as a New Therapeutic Frontier for Endometriosis
10个月前
Foghorn Therapeutics Advances Multi-Target Protein Degrader Pipeline with FHD-909 Phase 1 Trial Progressing
8个月前
Foghorn Therapeutics Secures $50 Million Financing to Advance First-in-Class Cancer Pipeline
去年
Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation
去年
Amivantamab Shows Promise in Colorectal Cancer as Phase 3 Trials Launch Following Encouraging Phase 1b/2 Results
去年
NXP800 Shows Promise in Overcoming Hormone Resistance in Advanced Prostate Cancer
第 1 页,共 4 页
上一页
下一页